Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis

Acta Ophthalmologica

Volumn 86, Issue SUPPL.242, 2008, Pages 14-19

  Hamacher, Thomas ^a   Airaksinen, Juhani ^b   Saarela, Ville ^b   Liinamaa, M Johanna ^b   Richter, Ulrich ^c   Ropo, Auli ^d  

^a Augenzentrum Dr Hamacher Praxis   (Germany)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c Practice   (Germany)

^d Santen Oy   (Finland)

Author keywords

Benzalkonium chloride; Glaucoma; Intraocular pressure; Preservative free; Tafluprost

Indexed keywords

BENZALKONIUM CHLORIDE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TAFLOTAN; TAFLUPROST; ANTIHYPERTENSIVE AGENT; PRESERVATIVE; PROSTAGLANDIN F;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BLEPHARITIS; BLURRED VISION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; EYE HYPEREMIA; EYE PAIN; EYELID ERYTHEMA; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR FOREIGN BODY SENSATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPTIC NERVE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRESERVATIVE FREE FORMULATION; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD; VITREOUS BODY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; OPEN ANGLE GLAUCOMA; PHARMACOKINETICS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 50549103133     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01381.x     Document Type: Article

References (20)

1. AGIS Investigators (2000): Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
2. Baudouin C, Pisella PJ, Goldschild M, Becquet F, De Saint Jean M & Béchetoille A (1999): Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology 106: 556-563.
3. Broadway DC, Grierson I & Hitchings RA (1993): Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 77: 590-596.
4. Broadway DC, Grierson I, O'Brien C & Hitchings RA (1994): Adverse effects of topical antiglaucoma medications. II. The outcome of filtration surgery. Arch Ophthalmol 112: 1446-1454.
5. European Glaucoma Society Guidelines (2008): Terminology and Guidelines for Glaucoma, 3rd edn. Editrice DOGMA, Savona, Italy: 117-153.
6. Furrer P, Mayer JM & Gurny R (2002): Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 53: 263-280.
7. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A & Zeyen T (2007): Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17: 341-349.
8. Kass MA, Heuer DK, Higginbotham EJ et al. (2002): The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713.
9. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E & the Early Manifest Glaucoma Trial Group (2003): Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol 121: 48-56.
10. Mundorf T, Wilcox KA, Ousler GW III, Welch D & Abelson MB (2003): Evaluation of the comfort of Alphagan P compared to Alphagan in irritated eyes. Adv Ther 20: 329-336.
11. 2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 26: 1691-1695.
12. Ota T, Murata H, Sugimoto E, Aihara M & Araie M (2005): Prostaglandin analogues and mouse intraocular pressure: Effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci 46: 2006-2011.
13. Pisella PJ, Pouliquen P & Baudouin C (2002): Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol 86: 418-423.
14. Schwab IR, Lindberg JV, Gioia VM, Benson WH & Chao GM (1992): Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 99: 197-202.
15. Smith JA, Albeitz J, Begley C, Caffery B, Nichols K, Schaumberg D & Schein O (2007): The epidemioloRy of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 5: 93-107.
16. Steuhl KP, Knorr M, Frohn A & Thiel HJ (1991): [Effect of antiglaucoma eyedrops on cell differentiation of the conjunctiva.] [In German.] Fortschr Ophthalmol 88: 865-869.
17. Sutton A, Gilvarry A & Ropo A (2007): A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 23: 359-365.
18. Takagi Y, Nakajima T, Shimazaki A et al. (2004): Pharmacological characteristics of AFP-168 (tafluprost), a prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78: 767-776.
19. Uusitalo H, Kaamiranta K & Ropo A (2008): Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol 86 (Suppl. 242): 7-13.
20. Zimmerman TJ, Hahn SR, Gelb L, Tan HK, Kim EE & Shah SN (2007): The effect of hyperaemia on open-angle glaucoma (OAG) treatment. [Abstract FP-GLA-036.] Annual Meeting of the European Society of Ophthalmology (SOE), 9-12 June 2007, Vienna.